AID Logo

Directory >> Corey Casper, MD, MPH


Contact Information

Corey Casper, MD, MPH

  • Professor of Medicine, Division of Allergy and Infectious Disease
  • Adjunct Professor Epidemiology, and Global Health University of Washington
  • Full Member Vaccine and Infectious Disease, Public Health Sciences and Clinical Research Divisions Fred Hutchinson Cancer Research Center
  • Head, Global Oncology, Fred Hutchinson Cancer Research Center
  • Associate Director, University of Washington / Fred Hutchinson Cancer Research Center, Center for AIDS Research, Seattle, Washington
  • Co-Director, UCI / Hutchinson Center Cancer Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • Associate Director, Fred Hutchinson Cancer Research Center / University of Washington Cancer Consortium, Seattle, Washington
  • Director, AIDS-Associated Malignancies and Infections Core, University of Washington / Fred Hutchinson Cancer Research, Center for AIDS Research, Seattle, Washington

Dr. Casper divides his time between engaging in research, teaching and clinical care. His research efforts focus on the transmission, acquisition, natural history, pathophysiology and treatment of infection-associated cancers with a special focus on the human herpesviruses (EBV and HHV-8). His immunology work described the first comprehensively-validated serologic assay for detection of antibodies to HHV-8, the original description of neutralizing antibodies to HHV-8 and their role in development of Kaposi Sarcoma (KS), and the characterization of gamma-delta T-cell activity in persons with chronic HHV-infection. He then made the first descriptions of the symptoms and viral replication patterns of HHV-8-infected persons without KS. As part of this work, he studied HHV-8 transmission among couples discordant for HHV-8 infection, and also collaborated with researchers in HIV prevention studies to describe epidemiologic risk factors for acquiring HHV-8 in many different cohorts.

As part of his research into HHV-8, Dr. Casper described the successful use of antiviral therapy for the treatment of multicentric Castleman disease (MCD) and followed this by the first randomized trial of an antiviral against HHV-8. He also utilized information from a large primary HIV clinic to show that the majority of patients with KS in the highly active antiretroviral therapy era have persistent disease, despite the receipt of highly active antiretroviral therapy (HAART) and chemotherapy. This work has informed current and future studies evaluating the role of antiviral drugs in the treatment and prevention of infection-associated cancers.

In 2004, Dr. Casper initiated collaboration with physician-scientists at the Uganda Cancer Institute (UCI) and the Kampala Cancer Registry, resulting in the formation of the Uganda Program in Cancer and Infectious Diseases (UPCID), now known as the UCI/Hutchinson Center Cancer Alliance. As Director of this alliance, based at the Fred Hutchinson Cancer Research Center, he established a translational clinical research site in Kampala. This site currently has conducted more than 2 dozen studies examining the control of HHV-8 replication, biomarkers for the prediction of KS development and successful treatment, the immunogenetics of infection-associated cancers, treatment of KS and Burkitt lymphoma, the role of nutrition in the development and treatment of infection-related cancers, and the discovery of novel pathogens associated with cancer. Under Dr. Casper's direction, research is being bolstered with the addition of a new cancer clinic and hospital, a quickly expanding training program, and a state-of-the-art molecular diagnostics laboratory.

Selected Publications

Mutyaba I, Phipps W, Krantz E, Goldman JD, Nambooze S, Orem J, Wabinga HR, Casper C. A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidences in Kyadondo County, Uganda, 1999 - 2008. Journal of Acquired Immune Deficiency Syndromes. April 2015.
Europe PubMed Central Abstract

Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncology, 15:966-74, 2014. PMID: 25042199.

Slyker JA, Casper C, Tapia K, et al. Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women. J Infect Dis. 2013; 207(12): 1798-1806.
Oxford Journals Abstract

Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011; 62: 157-70.
PubMed Abstract

Bateganya MH, Stanaway J, Brentlinger PE, Magaret AS, Wald A, Orem J, Casper C. Predictors of survival after a diagnosis of non-Hodgkin Lymphoma in a resource-limited setting: A retrospective study on the impact of HIV iInfection and its treatment. J Acquir Immune Defic Syndr. 2011; 56: 312-9.
PubMed Abstract

Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, Katongole-Mbidde E, Sande M, Ronald A, McAdam K, Huang M-L, Drolette L, Selke S, Wald A, Corey L, Casper C. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS ONE. 2009; 4: e4222.
PubMed Abstract

Nguyen HQ, Magaret AS, Van Rompaey SE, Kitahata MM, Wald A, Casper C. Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS. 2008; 22: 937-45.
PubMed Abstract

Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008; 198 23-30.
PubMed Abstract

to top